NewAmsterdam Pharma Company NV’s filing revealed that its Director Topper James N acquired Company’s shares for reported $46454.0 on Jun 24 ’25. In the deal valued at $18.43 per share,2,520 shares were bought. As a result of this transaction, Topper James N now holds 3,024,873 shares worth roughly $55.11 million.
Then, Topper James N bought 1,260 shares, generating $23,012 in total proceeds. Upon buying the shares at $18.26, the Director now owns 3,026,133 shares.
Before that, Kling Douglas F sold 100,000 shares. NewAmsterdam Pharma Company NV shares valued at $1,929,141 were divested by the Chief Operating Officer at a price of $19.29 per share. As a result of the transaction, Kling Douglas F now holds 44,000 shares, worth roughly $0.8 million.
Citigroup initiated its NewAmsterdam Pharma Company NV [NAMS] rating to a Buy in a research note published on June 17, 2025; the price target was $42. A number of analysts have revised their coverage, including Stifel’s analysts, who began to cover the stock in early June with a ‘”a Buy”‘ rating. Cantor Fitzgerald began covering NAMS with “an Overweight” recommendation on June 04, 2025. H.C. Wainwright started covering the stock on December 30, 2024. It rated NAMS as “a Buy”.
Price Performance Review of NAMS
On Tuesday, NewAmsterdam Pharma Company NV [NASDAQ:NAMS] saw its stock jump 0.61% to $18.22. Over the last five days, the stock has lost -0.98%. NewAmsterdam Pharma Company NV shares have fallen nearly -6.76% since the year began. Nevertheless, the stocks have fallen -29.11% over the past one year. While a 52-week high of $27.29 was reached on 01/02/25, a 52-week low of $14.06 was recorded on 04/07/25.
Levels Of Support And Resistance For NAMS Stock
The 24-hour chart illustrates a support level at 17.87, which if violated will result in even more drops to 17.53. On the upside, there is a resistance level at 18.66. A further resistance level may holdings at 19.11.
How much short interest is there in NewAmsterdam Pharma Company NV?
A steep rise in short interest was recorded in NewAmsterdam Pharma Company NV stocks on 2025-06-13, growing by 0.27 million shares to a total of 6.97 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 6.7 million shares. There was a rise of 3.9%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on May 15, 2024 when TD Cowen began covering the stock and recommended ‘”a Buy”‘ rating .
